Market Overview

Ariad Pharmaceuticals Expected To See Clinical Catalysts


SunTrust Robinson Humphrey sees potential upside of 65 percent in Ariad Pharmaceuticals, Inc. (NASDAQ: ARIA) given clinical catalysts and the company could be a takeover target.

Ariad's lead product Iclusig is a potent chronic myeloid leukemia (CML), drug, with the potential for broader use, while brigatinib is a potential best-in-class agent for ALK+ NSCLC (Non-Small Cell Lung Cancer (NSCLC).

"We estimate Iclusig U.S. peak sales in currently approved settings at ~$500MM on further penetration, while a second-line label expansion could add an additional ~$275MM by 2027," analyst Yatin Suneja wrote in a note.

Suneja expects brigatinib's (ALK/ROS1 inhibitor) U.S. approval and launch in the first quarter 2017 for the treatment of crizotinib-resistant (2ndline) ALK+ NSCLC.

"Given the drug's superior efficacy (PFS of 12.9 months vs. 6-9 months for competitors), we expect rapid uptake by physicians upon approval and estimate ~$320MM in U.S. peak sales in this indication by 2030," Suneja highlighted.

In addition, the analyst is also optimistic for success in brigatinib's ongoing Phase III ALTA-1L trial in first-line ALK+ NSCLC (interim data likely in 2018). The analyst said this subset is the biggest commercial opportunity, and estimate about $500 million in U.S. peak sales by 2030.

Meanwhile, Suneja noted that Ariad could be an M&A target with a takeout value estimated at about $29, as its two drugs target subsets of cancers with an estimated $1 billion plus in peak global sales for each.

"There is a scarcity of good commercial-stage oncology assets, and we believe there could be significant synergies with an established oncology player," Suneja added.

Suneja initiated the stock with a Buy rating and price target of $22.

At time of writing, shares of Ariad rose 3.67 percent to $13.85.

Latest Ratings for ARIA

Jan 2017DowngradesBuyHold
Jan 2017UpgradesUnderweightEqual-Weight
Jan 2017DowngradesBuyHold

View More Analyst Ratings for ARIA
View the Latest Analyst Ratings

Posted-In: SunTrust Yatin SunejaAnalyst Color Long Ideas Price Target Initiation Analyst Ratings Trading Ideas


Related Articles (ARIA)

View Comments and Join the Discussion!

Olive Garden Dominates The Darden Story Post Earnings

Recode: Pinterest's Recent Exec Hire Isn't A Sign Of Looming IPO